RecruitingNCT06321757

PREVAIL Paclitaxel-coated Balloon in Small Coronary Disease and High-bleeding Risk Patients


Sponsor

Fundación EPIC

Enrollment

501 participants

Start Date

Feb 26, 2024

Study Type

OBSERVATIONAL

Conditions

Summary

Post-market, prospective, observational, multicenter, non-intervention study, to demonstrate the effectiveness of drug-coated ballon (DCB)therapy in real-world patients with small native vessel coronary artery disease, and to demonstrate the safety of short dual antiplatelet therapy (7 days) in high-bleeding risk patients with native small vessel coronary artery disease treated with DCB therapy. A percutaneous coronary intervention (PCI) with DCB will be performed in patients with native vessel coronary artery disease based on the criterion of the treating physician.


Eligibility

Min Age: 18 Years

Inclusion Criteria7

  • Patients with:
  • PCI with DCB on native arteries with diameters < 3 mm.
  • Indication for PCI in acute coronary syndrome or chronic coronary syndrome or silent angina with an indication for PCI.
  • syndrome or silent angina with an indication for PCI.
  • If previous lesion preparation was required after which angiographic residual lesion should not exist with diameter stenosis > 30% or flow-limiting coronary dissections.
  • All antithrombotic therapies administered prior to the procedure are accepted. Still, they can be changed after the procedure.
  • Capacity to understand and sign the written informed consent.

Exclusion Criteria11

  • Patients with:
  • Concomitant lesions on vessels > 3 mm in diameter in the same coronary territory.
  • PCI on in-stent restenoses.
  • PCI on culprit lesions of acute coronary syndrome with ST segment elevation.
  • Patients with an indication for PCI on additional non-culprit lesions of acute coronary syndrome with ST segment elevation may be included in the study, if only non-culprit lesions are considered for the study.
  • Life expectancy <12 months
  • Pregnancy.
  • Participation in clinicaltrials.
  • Inability to give the written informed consent.
  • Past medical history of stent thrombosis.
  • Indication for dual antiplatelet therapy for a different reason.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICEPercutaneous Coronary Intervention with DCB and DAPT

* Patients with PCI (DCB) + standard DAPT standard dual antiplatelet therapy (DAPT) * Patients with PCI (DCB) + short DAPT


Locations(18)

Clinica Mediterranea

Naples, Italy

Ulslo-H.Santa Cruz

Carnaxide, Portugal

ULS Santa Maria

Lisbon, Portugal

Hospital General Universitario de Albacete

Albacete, Spain

Hospital General Universitario Dr. Balmis

Alicante, Spain

Hospital Universitario de Cruces

Barakaldo, Spain

University Hospital HM Montepríncipe

Boadilla del Monte, Spain

Hospital General Universitario de Ciudad Real

Ciudad Real, Spain

Hospital Universitario Clinico San Cecilio

Granada, Spain

Hospital Universitario Juan Ramon Jimenez

Huelva, Spain

Hospital Universitari de Bellvitge

L'Hospitalet de Llobregat, Spain

Hospital Universitario de Gran Canaria Doctor Negrín

Las Palmas de Gran Canaria, Spain

Hospital Universitario de Leon

León, Spain

Hospital Universitario de La Princesa

Madrid, Spain

Hospital Universitario de Canarias

San Cristóbal de La Laguna, Spain

Hospital Universitario Virgen del Rocío

Seville, Spain

Hospital Universitario Y Politecnico La Fe

Valencia, Spain

Hospital Clinico Universitario de Valladolid

Valladolid, Spain

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06321757


Related Trials